Phase II Study of Troxacitabine (BCH-4556) in Patients With Advanced and/or Metastatic Renal Cell Carcinoma: A Trial of the National Cancer Institute of Canada-Clinical Trials Group
- 15 April 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (8) , 1524-1529
- https://doi.org/10.1200/jco.2003.03.057
Abstract
Purpose: A multi-institution phase II study was undertaken by National Cancer Institute of Canada–Clinical Trials Group to evaluate the efficacy and toxicity of intravenous troxacitabine (Troxatyl; Shire Pharmaceuticals Plc, Laval, Quebec, Canada), in patients with renal cell carcinoma. Patients and Methods: Between June 1999 and March 2000, 35 patients (24 male) with a mean age of 60 years who had advanced and/or metastatic disease were treated with troxacitabine given as an intravenous infusion over 30 minutes at a dose of 10 mg/m2 intravenously, once every 3 weeks. Results: Of the 33 of 35 patients evaluable for response, there were two confirmed partial responses, 21 patients had stable disease (median duration, 4.4 months), and 10 patients had progressive disease. Eight patients remained stable for more than 6 months, of whom six remain free of progression. The most common drug-related nonhematologic toxicities observed were skin rash (77.1%), hand-foot syndrome (68.6%), alopecia (51.4%), fatigue (51.4%), and nausea (57.1%). Out of a total of 145 cycles of treatment, 98 were given without steroid premedication, whereas 47 cycles were given with steroid premedication. Without premedication, skin rash occurred in 37% of cycles compared with 26% when steroids were given prophylactically. Conclusion: Troxacitabine given at a dose of 10 mg/m2 once every 3 weeks was well tolerated in patients with metastatic renal cell cancer, with common toxicities being a moderate to severe granulocytopenia and skin rash. Steroid premedication may reduce the frequency and severity of the skin rash. Our current study suggests that the nucleoside analog troxacitabine may have modest activity against renal cell carcinoma; however, larger studies are required to confirm this.Keywords
This publication has 18 references indexed in Scilit:
- Phase I and Pharmacokinetic Study of Novel l-Nucleoside Analog Troxacitabine Given as a 30-Minute Infusion Every 21 DaysJournal of Clinical Oncology, 2002
- Phase II Study of Troxacitabine, a Novel Dioxolane Nucleoside Analog, in Patients With Refractory LeukemiaJournal of Clinical Oncology, 2002
- Phase II Trial of Thalidomide for Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2002
- Phase II Trial of Irofulven (6-Hydroxymethylacylfulvene) for Patients with Advanced Renal Cell CarcinomaInvestigational New Drugs, 2001
- A Phase II Trial of Weekly Intravenous Ranpirnase (Onconase®), a Novel Ribonuclease in Patients with Metastatic Kidney CancerInvestigational New Drugs, 2001
- The current status of interferon-α treatment in advanced renal cancerBJU International, 2001
- Troxacitabine, A Novel Dioxolane Nucleoside Analog, Has Activity in Patients With Advanced LeukemiaJournal of Clinical Oncology, 2001
- Phase II Study of Pyrazoloacridine in Metastatic Renal Cell CarcinomaInvestigational New Drugs, 2001
- Kidney cancerThe Lancet, 1998
- Cancer Statistics, 1987CA: A Cancer Journal for Clinicians, 1987